Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).
William Sandborn, MD, principal investigator of the Crohn's disease study, said the results offer new hope to the more than one million Americans who suffer from inflammatory bowel disease (IBD) and do not respond to treatment. Both studies showed that the use of vedolizumab resulted in remission and discontinued use of prednisone, a common yet difficult to tolerate drug used to treat both diseases.
"The two trials showed highly encouraging results for patients suffering from moderate-to-severe Crohn's disease and ulcerative colitis when conventional therapy such as steroids, immune suppressive drugs and anti-tumor necrosis factor (TNF) biologic drugs failed," said Sandborn, of the Division of Gastroenterology at UC San Diego School of Medicine and director of the Inflammatory Bowel Disease Center at UC San Diego Health System. "This is a disease modifying drug. In many cases of patients with ulcerative colitis, complete healing of the bowel was observed and maintained with continued use of vedolizumab."
Vedolizumab is targeted to disease within the digestive tract so other areas of the body remain unaffected. It blocks immune system cells that release proteins called cytokines that trigger inflammation, causing tissue damage and diarrhea to move into the small intestine and colon. The targeted nature of the medication helps reduce troublesome side effects such as weight gain, nausea and headaches caused by other treatment options. Current treatments such as steroids and immunosuppressive medications broadly suppress the immune system, which can also put the patient at risk for infections.
"Inflammatory bowel disease causes severe ongoing bouts of illness that adversely affect a patient's quality of life at home and work," said Sandborn. "These latest findings will potentially lead to a new drug therapy that will improve a patient's overall lifestyle."
This video is not supported by your browser at this time.
Crohn's disease and ulcerative colitis are forms of inflammatory autoimmune diseases, impacting the small intestine and colon. Clinical symptoms include abdominal pain, diarrhea, intestinal bleeding, fecal urgency and weight loss. Serious complications such as bowel obstruction, colon cancer, malnutrition and abscesses can also occur, resulting in hospitalization and the possible surgical removal of portions of the bowel and colon.
Eight hundred and ninety five patients were part of the ulcerative colitis trial conducted in 34 countries, and 1,115 patients were part of the Crohn's disease clinical trial conducted in 39 countries. Eligible patients for both trials were between 18 and 80-years-old and were treated for 52 weeks in the placebo-controlled studies. Benefits could be seen six weeks into the study.
Explore further: Study finds potential new drug therapy for Crohn's disease
Medical Xpress on facebook
Related Stories
Study identifies potential new class of drug for treating ulcerative colitis
Aug 15, 2012
An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University ...
Study finds potential new drug therapy for Crohn's disease
Oct 17, 2012
Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn's Disease, according to researchers at the University of California San ...
Biomarkers discovered for inflammatory bowel disease
May 21, 2013
Using the Department of Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers have identified a number of biomarkers for inflammatory bowel disease (IBD), which could help with earlier diagnosis and ...
Inflammatory bowel disease raises risk of melanoma
May 20, 2013
Patients with inflammatory bowel disease (IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent greater risk for the disease. ...
Opening up new pathways for treating inflammatory bowel diseases
Aug 12, 2013
Inflammatory bowel disease (IBD) is a chronic condition affecting 1 in 250 people in Europe. Current treatment is ineffective for many. However, a team of European scientists has increased understanding of ...
Recommended for you
Virus changes its stripes: Outbreak in Panama brought Latin America's first human cases of eastern equine encephalitis
5 seconds ago
In the summer of 2010, the eastern Panamanian province of Darien experienced a phenomenon that had never been seen before in Latin America: a human outbreak of eastern equine encephalitis.
US issues advisory for Cuba over cholera cases
1 hour ago
The United States has issued an advisory for travelers to Cuba after several foreign visitors were sickened by cholera in recent weeks.
Tuberculosis genomes portray secrets of pathogen's success
1 hour ago
By any measure, tuberculosis (TB) is a wildly successful pathogen. It infects as many as two billion people in every corner of the world, with a new infection of a human host estimated to occur every second.
MERS virus discovered in bat near site of outbreak in Saudi Arabia
2 hours ago
A 100% genetic match for Middle East Respiratory Syndrome (MERS) has been discovered in an insect-eating bat in close proximity to the first known case of the disease in Saudi Arabia. The discovery points ...
Scientists find another flu virus in Chinese chickens
2 hours ago
Scientists studying the H7N9 bird flu virus that has killed more than 40 people since March said Wednesday they had discovered another H7-type virus lurking in chickens in China.
Experimental Ebola treatment protects some primates even after disease symptoms appear
3 hours ago
Scientists have successfully treated the deadly Ebola virus in infected animals following onset of disease symptoms, according to a report published online today in Science Translational Medicine. The results show promis ...
User comments
© Medical Xpress 2011-2013, Phys.org network
Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).
William Sandborn, MD, principal investigator of the Crohn's disease study, said the results offer new hope to the more than one million Americans who suffer from inflammatory bowel disease (IBD) and do not respond to treatment. Both studies showed that the use of vedolizumab resulted in remission and discontinued use of prednisone, a common yet difficult to tolerate drug used to treat both diseases.
"The two trials showed highly encouraging results for patients suffering from moderate-to-severe Crohn's disease and ulcerative colitis when conventional therapy such as steroids, immune suppressive drugs and anti-tumor necrosis factor (TNF) biologic drugs failed," said Sandborn, of the Division of Gastroenterology at UC San Diego School of Medicine and director of the Inflammatory Bowel Disease Center at UC San Diego Health System. "This is a disease modifying drug. In many cases of patients with ulcerative colitis, complete healing of the bowel was observed and maintained with continued use of vedolizumab."
Vedolizumab is targeted to disease within the digestive tract so other areas of the body remain unaffected. It blocks immune system cells that release proteins called cytokines that trigger inflammation, causing tissue damage and diarrhea to move into the small intestine and colon. The targeted nature of the medication helps reduce troublesome side effects such as weight gain, nausea and headaches caused by other treatment options. Current treatments such as steroids and immunosuppressive medications broadly suppress the immune system, which can also put the patient at risk for infections.
"Inflammatory bowel disease causes severe ongoing bouts of illness that adversely affect a patient's quality of life at home and work," said Sandborn. "These latest findings will potentially lead to a new drug therapy that will improve a patient's overall lifestyle."
This video is not supported by your browser at this time.
Crohn's disease and ulcerative colitis are forms of inflammatory autoimmune diseases, impacting the small intestine and colon. Clinical symptoms include abdominal pain, diarrhea, intestinal bleeding, fecal urgency and weight loss. Serious complications such as bowel obstruction, colon cancer, malnutrition and abscesses can also occur, resulting in hospitalization and the possible surgical removal of portions of the bowel and colon.
Eight hundred and ninety five patients were part of the ulcerative colitis trial conducted in 34 countries, and 1,115 patients were part of the Crohn's disease clinical trial conducted in 39 countries. Eligible patients for both trials were between 18 and 80-years-old and were treated for 52 weeks in the placebo-controlled studies. Benefits could be seen six weeks into the study.
Explore further: Study finds potential new drug therapy for Crohn's disease
Medical Xpress on facebook
Related Stories
Study identifies potential new class of drug for treating ulcerative colitis
Aug 15, 2012
An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University ...
Study finds potential new drug therapy for Crohn's disease
Oct 17, 2012
Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn's Disease, according to researchers at the University of California San ...
Biomarkers discovered for inflammatory bowel disease
May 21, 2013
Using the Department of Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers have identified a number of biomarkers for inflammatory bowel disease (IBD), which could help with earlier diagnosis and ...
Inflammatory bowel disease raises risk of melanoma
May 20, 2013
Patients with inflammatory bowel disease (IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent greater risk for the disease. ...
Opening up new pathways for treating inflammatory bowel diseases
Aug 12, 2013
Inflammatory bowel disease (IBD) is a chronic condition affecting 1 in 250 people in Europe. Current treatment is ineffective for many. However, a team of European scientists has increased understanding of ...
Recommended for you
Virus changes its stripes: Outbreak in Panama brought Latin America's first human cases of eastern equine encephalitis
5 seconds ago
In the summer of 2010, the eastern Panamanian province of Darien experienced a phenomenon that had never been seen before in Latin America: a human outbreak of eastern equine encephalitis.
US issues advisory for Cuba over cholera cases
1 hour ago
The United States has issued an advisory for travelers to Cuba after several foreign visitors were sickened by cholera in recent weeks.
Tuberculosis genomes portray secrets of pathogen's success
1 hour ago
By any measure, tuberculosis (TB) is a wildly successful pathogen. It infects as many as two billion people in every corner of the world, with a new infection of a human host estimated to occur every second.
MERS virus discovered in bat near site of outbreak in Saudi Arabia
2 hours ago
A 100% genetic match for Middle East Respiratory Syndrome (MERS) has been discovered in an insect-eating bat in close proximity to the first known case of the disease in Saudi Arabia. The discovery points ...
Scientists find another flu virus in Chinese chickens
2 hours ago
Scientists studying the H7N9 bird flu virus that has killed more than 40 people since March said Wednesday they had discovered another H7-type virus lurking in chickens in China.
Experimental Ebola treatment protects some primates even after disease symptoms appear
3 hours ago
Scientists have successfully treated the deadly Ebola virus in infected animals following onset of disease symptoms, according to a report published online today in Science Translational Medicine. The results show promis ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment